How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
Background There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriaten...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2023-01, Vol.31 (1), p.37, Article 37 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 37 |
| container_title | Supportive care in cancer |
| container_volume | 31 |
| creator | Peipert, John Devin Shaunfield, Sara Kaiser, Karen Moreno, Patricia I. Fox, Rina S. Kircher, Sheetal Mohindra, Nisha Ip, Edward Zhao, Fengmin Wagner, Lynne Cella, David |
| description | Background
There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients.
Methods
Patients with ovarian cancer (Study 1:
N
= 21; on treatment), lymphoma (Study 2:
N
= 14; on treatment), and colorectal or lung cancer (Study 3:
N
= 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied.
Results
Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies.
Conclusion
This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment. |
| doi_str_mv | 10.1007/s00520-022-07484-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10356672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A730419879</galeid><sourcerecordid>A730419879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-4c551890025644b07dab4bcfef505744f020b4c5b393c4c2b55f27834c98f8e93</originalsourceid><addsrcrecordid>eNp9kk9vFSEUxYnR2Gf1C7gwJG7cTOXvMLNqmkatSRM3uiYMcxlpGHgCT9NvL6-vPq0xwuIm8DsH7s1B6CUlZ5QQ9bYQIhnpCGMdUWIQnXqENlRw3inOx8doQ0ZBO8GlPEHPSrkhhCol2VN0wnvJZPPYIH-VfuA54a2pHmIt2McKeZuhYhNnnKFsU6s1YYOLj0uAzldY8RLSZEKjZ29NTRknh62JFjKuGUxdm1lTBchm8sHX2_Pn6IkzocCL-3qKvrx_9_nyqrv-9OHj5cV1Z6VgtRNWSjqMhDDZCzERNZtJTNaBk0QqIRxhZGrQxEduhWWTlI6pgQs7Dm6AkZ-i84PvdjetMNv2kWyC3ma_mnyrk_H64U30X_WSvmtKuOx7xZrDm3uHnL7toFS9-mIhBBMh7YpmSkqpxoH2DX39F3qTdjm2_u6oNnHe1pFaTADto0vtYbs31ReKE0HHQe0_fvYPqu0ZVm9TBOfb-QMBOwhsTqVkcMcmKdH7hOhDQnRLiL5LiFZN9OrP8RwlvyLRAH4ASruKC-TfLf3H9ifbGsXS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2755001333</pqid></control><display><type>article</type><title>How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Peipert, John Devin ; Shaunfield, Sara ; Kaiser, Karen ; Moreno, Patricia I. ; Fox, Rina S. ; Kircher, Sheetal ; Mohindra, Nisha ; Ip, Edward ; Zhao, Fengmin ; Wagner, Lynne ; Cella, David</creator><creatorcontrib>Peipert, John Devin ; Shaunfield, Sara ; Kaiser, Karen ; Moreno, Patricia I. ; Fox, Rina S. ; Kircher, Sheetal ; Mohindra, Nisha ; Ip, Edward ; Zhao, Fengmin ; Wagner, Lynne ; Cella, David</creatorcontrib><description>Background
There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients.
Methods
Patients with ovarian cancer (Study 1:
N
= 21; on treatment), lymphoma (Study 2:
N
= 14; on treatment), and colorectal or lung cancer (Study 3:
N
= 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied.
Results
Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies.
Conclusion
This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment.</description><identifier>ISSN: 0941-4355</identifier><identifier>ISSN: 1433-7339</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-022-07484-7</identifier><identifier>PMID: 36525100</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Lung cancer ; Lymphomas ; Medical colleges ; Medicine ; Medicine & Public Health ; Nursing ; Nursing Research ; Oncology ; Oncology, Experimental ; Ovarian cancer ; Ovarian Neoplasms ; Pain Medicine ; Patient satisfaction ; Patients ; Questionnaires ; Rehabilitation Medicine ; Side effects</subject><ispartof>Supportive care in cancer, 2023-01, Vol.31 (1), p.37, Article 37</ispartof><rights>The Author(s) 2022. corrected publication 2023</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>COPYRIGHT 2023 Springer</rights><rights>The Author(s) 2022. corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022, corrected publication 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-4c551890025644b07dab4bcfef505744f020b4c5b393c4c2b55f27834c98f8e93</citedby><cites>FETCH-LOGICAL-c542t-4c551890025644b07dab4bcfef505744f020b4c5b393c4c2b55f27834c98f8e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-022-07484-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-022-07484-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36525100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peipert, John Devin</creatorcontrib><creatorcontrib>Shaunfield, Sara</creatorcontrib><creatorcontrib>Kaiser, Karen</creatorcontrib><creatorcontrib>Moreno, Patricia I.</creatorcontrib><creatorcontrib>Fox, Rina S.</creatorcontrib><creatorcontrib>Kircher, Sheetal</creatorcontrib><creatorcontrib>Mohindra, Nisha</creatorcontrib><creatorcontrib>Ip, Edward</creatorcontrib><creatorcontrib>Zhao, Fengmin</creatorcontrib><creatorcontrib>Wagner, Lynne</creatorcontrib><creatorcontrib>Cella, David</creatorcontrib><title>How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Background
There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients.
Methods
Patients with ovarian cancer (Study 1:
N
= 21; on treatment), lymphoma (Study 2:
N
= 14; on treatment), and colorectal or lung cancer (Study 3:
N
= 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied.
Results
Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies.
Conclusion
This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment.</description><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Drug therapy</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Female</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lymphomas</subject><subject>Medical colleges</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms</subject><subject>Pain Medicine</subject><subject>Patient satisfaction</subject><subject>Patients</subject><subject>Questionnaires</subject><subject>Rehabilitation Medicine</subject><subject>Side effects</subject><issn>0941-4355</issn><issn>1433-7339</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kk9vFSEUxYnR2Gf1C7gwJG7cTOXvMLNqmkatSRM3uiYMcxlpGHgCT9NvL6-vPq0xwuIm8DsH7s1B6CUlZ5QQ9bYQIhnpCGMdUWIQnXqENlRw3inOx8doQ0ZBO8GlPEHPSrkhhCol2VN0wnvJZPPYIH-VfuA54a2pHmIt2McKeZuhYhNnnKFsU6s1YYOLj0uAzldY8RLSZEKjZ29NTRknh62JFjKuGUxdm1lTBchm8sHX2_Pn6IkzocCL-3qKvrx_9_nyqrv-9OHj5cV1Z6VgtRNWSjqMhDDZCzERNZtJTNaBk0QqIRxhZGrQxEduhWWTlI6pgQs7Dm6AkZ-i84PvdjetMNv2kWyC3ma_mnyrk_H64U30X_WSvmtKuOx7xZrDm3uHnL7toFS9-mIhBBMh7YpmSkqpxoH2DX39F3qTdjm2_u6oNnHe1pFaTADto0vtYbs31ReKE0HHQe0_fvYPqu0ZVm9TBOfb-QMBOwhsTqVkcMcmKdH7hOhDQnRLiL5LiFZN9OrP8RwlvyLRAH4ASruKC-TfLf3H9ifbGsXS</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Peipert, John Devin</creator><creator>Shaunfield, Sara</creator><creator>Kaiser, Karen</creator><creator>Moreno, Patricia I.</creator><creator>Fox, Rina S.</creator><creator>Kircher, Sheetal</creator><creator>Mohindra, Nisha</creator><creator>Ip, Edward</creator><creator>Zhao, Fengmin</creator><creator>Wagner, Lynne</creator><creator>Cella, David</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?</title><author>Peipert, John Devin ; Shaunfield, Sara ; Kaiser, Karen ; Moreno, Patricia I. ; Fox, Rina S. ; Kircher, Sheetal ; Mohindra, Nisha ; Ip, Edward ; Zhao, Fengmin ; Wagner, Lynne ; Cella, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-4c551890025644b07dab4bcfef505744f020b4c5b393c4c2b55f27834c98f8e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Drug therapy</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Female</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lymphomas</topic><topic>Medical colleges</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms</topic><topic>Pain Medicine</topic><topic>Patient satisfaction</topic><topic>Patients</topic><topic>Questionnaires</topic><topic>Rehabilitation Medicine</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peipert, John Devin</creatorcontrib><creatorcontrib>Shaunfield, Sara</creatorcontrib><creatorcontrib>Kaiser, Karen</creatorcontrib><creatorcontrib>Moreno, Patricia I.</creatorcontrib><creatorcontrib>Fox, Rina S.</creatorcontrib><creatorcontrib>Kircher, Sheetal</creatorcontrib><creatorcontrib>Mohindra, Nisha</creatorcontrib><creatorcontrib>Ip, Edward</creatorcontrib><creatorcontrib>Zhao, Fengmin</creatorcontrib><creatorcontrib>Wagner, Lynne</creatorcontrib><creatorcontrib>Cella, David</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peipert, John Devin</au><au>Shaunfield, Sara</au><au>Kaiser, Karen</au><au>Moreno, Patricia I.</au><au>Fox, Rina S.</au><au>Kircher, Sheetal</au><au>Mohindra, Nisha</au><au>Ip, Edward</au><au>Zhao, Fengmin</au><au>Wagner, Lynne</au><au>Cella, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>31</volume><issue>1</issue><spage>37</spage><pages>37-</pages><artnum>37</artnum><issn>0941-4355</issn><issn>1433-7339</issn><eissn>1433-7339</eissn><abstract>Background
There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients.
Methods
Patients with ovarian cancer (Study 1:
N
= 21; on treatment), lymphoma (Study 2:
N
= 14; on treatment), and colorectal or lung cancer (Study 3:
N
= 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied.
Results
Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies.
Conclusion
This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36525100</pmid><doi>10.1007/s00520-022-07484-7</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2023-01, Vol.31 (1), p.37, Article 37 |
| issn | 0941-4355 1433-7339 1433-7339 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10356672 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Cancer Cancer patients Cancer therapies Care and treatment Drug therapy Drug-Related Side Effects and Adverse Reactions Female Humans Lung cancer Lymphomas Medical colleges Medicine Medicine & Public Health Nursing Nursing Research Oncology Oncology, Experimental Ovarian cancer Ovarian Neoplasms Pain Medicine Patient satisfaction Patients Questionnaires Rehabilitation Medicine Side effects |
| title | How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A22%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20do%20patients%20interpret%20and%20respond%20to%20a%20single-item%20global%20indicator%20of%20cancer%20treatment%20tolerability?&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Peipert,%20John%20Devin&rft.date=2023-01-01&rft.volume=31&rft.issue=1&rft.spage=37&rft.pages=37-&rft.artnum=37&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-022-07484-7&rft_dat=%3Cgale_pubme%3EA730419879%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2755001333&rft_id=info:pmid/36525100&rft_galeid=A730419879&rfr_iscdi=true |